Waterloo Capital L.P. Takes $217,000 Position in Novo Nordisk A/S (NYSE:NVO)

Waterloo Capital L.P. bought a new stake in Novo Nordisk A/S (NYSE:NVOFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,096 shares of the company’s stock, valued at approximately $217,000.

Other institutional investors have also modified their holdings of the company. Westside Investment Management Inc. increased its holdings in shares of Novo Nordisk A/S by 83.3% in the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after purchasing an additional 649 shares during the period. Lazard Asset Management LLC grew its holdings in Novo Nordisk A/S by 182.2% during the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after acquiring an additional 964,640 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Novo Nordisk A/S by 38.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock worth $9,781,000 after acquiring an additional 26,067 shares during the period. One Capital Management LLC acquired a new position in Novo Nordisk A/S during the third quarter worth $203,000. Finally, Advisor Resource Council acquired a new position in Novo Nordisk A/S during the fourth quarter worth $997,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.5 %

Shares of NYSE:NVO opened at $143.63 on Tuesday. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $143.94. The stock’s fifty day simple moving average is $130.05 and its 200-day simple moving average is $119.51. The company has a market capitalization of $644.54 billion, a P/E ratio of 49.53, a P/E/G ratio of 1.48 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The business had revenue of $9.52 billion for the quarter, compared to the consensus estimate of $9.23 billion. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

NVO has been the topic of a number of recent analyst reports. Argus upped their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. The Goldman Sachs Group started coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $145.67.

Read Our Latest Report on NVO

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Further Reading

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.